[A19-62] Pembrolizumab (squamous NSCLC, combination chemotherapy) - Addendum to commission A19-31

Last updated 19.09.2019

Project no.:
A19-62

Commission:
Commission awarded on 05.08.2019 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults

Result of dossier assessment:

PD-L1 expression < 50%: indication of major added benefit. PD-L1 expression ≥ 50%: added benefit not proven

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

19.09.2019

Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations

After a methodological uncertainty has been resolved, analyses on overall survival are now usable

Federal Joint Committee (G-BA)

2019-09-19 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.